An observational study in Preeclampsia, Preterm Birth and Pregnancy Complications, sponsored by CHU de Quebec-Universite Laval. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-16.
Sponsored by CHU de Quebec-Universite Laval · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Pre-Eclampsia with a site in Canada — 4 open to participants now, 5 under way, 1 of them phase 3. Pre-Eclampsia · Canada.
Among the 31 studies in Pre-Eclampsia with a site in Canada, this one has the largest planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2015, is one of 12 observational ones, and was the 19th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →4 of the 31 studies in Pre-Eclampsia with a site in Canada are open now. Recruiting first, the newest first:
University of Calgary · Sites in Canada, Belgium, Denmark and 4 more countries
Ages 18+ · Women only
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+ · Women only
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Sites in Canada
Ages 18+ · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 7,845 is above the median of 165 across 397 observational studies indexed under Pre-Eclampsia.
Median enrollment 73 across the 19 interventional studies, 370 across the 12 observational. Of the 21 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
CHU de Quebec-Universite Laval is the lead sponsor of 137 studies on the registry; 27 are open to participants now.
CHU de Quebec-Universite Laval has 5 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 31 studies in Pre-Eclampsia with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Biobank includes data and biological specimens of women from three original studies: 1) First-trimester Prediction of Preeclampsia (PREDICTION Study, NCT02189148), 2) Pre-Eclampsia And growth Retardation, an evaluative Longitudinal study (PEARL Study, NCT02379832), 3) Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial (NCT02280031) and 4)PREDICTION2: Prediction of Preeclampsia and other Pregnancy Complications Following Combined Iterative Screening.
This Biobank is comprised of: 1) medical, social, obstetrical and ultrasonographic data, 2) human biological samples (maternal plasma, serum and buffy coat, maternal urine, cord blood) and 3) the results derived from these (biochemical or ultrasonographic markers, genetics, risk calculations ...)
According to each study:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6/7 weeks of gestation (N=7600 maximum).
Other: Observational
The women recruited in the biobank through the PEARL Study (NCT02379832) are : 1. low-risk pregnant women between 11 and 13 6/7 weeks of gestation (controls, N=45) 2. pregnant women with diagnosis of preeclampsia between 20 and 41 6/7 weeks of gestation (cases, N=45)
Other: Observational
The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3/7 and 13 6/7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.
Other: Observational
The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6/7 weeks of gestation (N=1000 maximum).
Other: Observational
Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)
Other: Observational
All women of the biobank have provided: 1. blood samples (plasma, serum and Buffy-coat) 2. urine samples 3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history) 4. mean arterial blood pressure 5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases) 6. access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)
early onset preeclampsia
Preeclampsia will be defined according to the Canadian Guidelines for Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy guidelines, as de novo hypertension with diastolic blood pressure \>90 mmHg on two occasions at least four hours apart, after 20 weeks of pregnancy, associated with proteinuria ≥300 mg/24 h or at least '2 +' protein on urine dipstick or an adverse conditions
Time frame: diagnosed between 20 and 34 weeks of gestation
Severe preeclampsia
Severe Preeclampsia will be defined by the presence of at least one of the following adverse condition: 1) systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 110 mmHg after 4 h of bed rest, 2) proteinuria ≥ 5 g/24 h or at least '3 +' protein on urine dipstick, or 3) oliguria \< 400 ml/24 h; 4) cerebral or visual disturbances; epigastric pain; pulmonary edema or cyanosis; thrombocytopenia \<100,000mm
Time frame: between 20 and 42 weeks of gestation
Fetal growth restriction
Fetal growth restriction will be defined as a birth weight below the 10th centile (or below the 3rd centile for severe FGR) of Canadian reference growth charts.
Time frame: between 20 and 42 weeks of gestation
spontaneous preterm birth
sPTB is a birth occuring spontaneously between 20 and 36 6/7 weeks of gestation
Time frame: between 20 and 36 6/7 weeks of gestation
Fetal aneuploidies
Any fetal chromosome that has an abnormal number of copies. Example: trisomy 13, 18 or 21.
Time frame: diagnosed during or after pregnancy
Plan to share: Yes — We will publish the results linked to the data collected. We will share these data with other groups that are interested in research on preeclampsia and other pregnancy complications.
No publications or documents are linked to this record.
Started Apr 2015 (actual). Primary completion is estimated for Apr 2025, 120 months after the start.
Of 191 non-industry observational studies under Pre-Eclampsia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 120 months is above that.
Counting every sponsor, half of 200 studies reached it within 30 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHU de Quebec-Universite Laval →